Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This will be an open label study using daily does of up to 126mg/day of Concerta in the
treatment of children and adolescents, ages 12-17, who meet DSM-IV criteria for ADHD.
Specific hypotheses are as follows:
Hypothesis 1: Children and adolescents with ADHD will have significantly higher ACC and DLPFC
Glutamate/myo-Inositol containing compounds (Glu/Ino) and Glutamate/creatine +
phosphocreatine (Glu/Cr) than matched HCS.
Hypothesis 2: After six weeks of treatment, OROS methylphenidate will lower ACC and DLPFC
Glu/Ino and Glu/Cr levels in children with ADHD who are methylphenidate responders.